人类猴痘：生物学、流行病学、治疗选择和小分子抑制剂的研发。
Human mpox: Biology, epidemiology, therapeutic options, and development of small molecule inhibitors.
机构信息
Shanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
出版信息
Med Res Rev. 2023 Jul;43(4):1019-1037. doi: 10.1002/med.21943. Epub 2023 Mar 9.
Although monkeypox (mpox) has been endemic in Western and Central Africa for 50 years, it has not received sufficient prophylactic and therapeutical attention to avoid evolving into an epidemic. From January 2022 to January 2023, more than 84,000 of mpox cases were reported from 110 countries worldwide. Case numbers appear to be rising every day, making mpox an increasing global public health threat for the foreseeable future. In this perspective, we review the known biology and epidemiology of mpox virus, together with the latest therapeutic options available for mpox treatment. Further, small molecule inhibitors against mpox virus and the future directions in this field are discussed as well.
虽然猴痘（mpox）在西非和中非已经流行了 50 年，但它没有得到足够的预防和治疗关注，从而避免了演变成一种流行病。从 2022 年 1 月到 2023 年 1 月，全球 110 个国家报告了超过 84000 例猴痘病例。病例数似乎每天都在增加，这使得猴痘在可预见的未来成为一个日益严重的全球公共卫生威胁。有鉴于此，我们综述了已知的猴痘病毒的生物学和流行病学特征，以及目前可用于治疗猴痘的最新治疗选择。此外，我们还讨论了针对猴痘病毒的小分子抑制剂以及该领域的未来发展方向。
Zotero 插件